BETTER UNDERSTANDING THE MECHANISMS OF NEURODEGENERATIVE DISEASE

 

 TDP-43 mediated neurodegeneration in Amyotrophic Lateral Sclerosis (ALS) 

Like tau acetylation and phosphorylation in Alzheimer’s Disease, TDP-43 modifications similarly promote aberrant pathology seen in diseased brain and spinal cord of ALS and FTLD-TDP patients. Understanding such post-translational mechanisms could lead to better therapeutic avenues to pursue for ALS, FTD and other diseases characterized by TDP-43 pathology.

 

 

2 Responses to “TDP-43 in Amyotrophic Lateral Sclerosis”

  1. Bob Gregory

    Are you doing any clinical trial for your work with ALS?

    Reply
    • Ping Wang

      We are doing basic research , and not doing any clinical trial.

      Reply

Leave a Reply